1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > Urinary Tract Infections Global Clinical Trials Review, H2, 2014

Urinary Tract Infections Global Clinical Trials Review, H2, 2014

Summary

GlobalData's clinical trial report, “Urinary Tract Infections Global Clinical Trials Review, H2, 2014" provides data on the Urinary Tract Infections clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Urinary Tract Infections. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Urinary Tract Infections. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each
- Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type
- Listings of discontinued trials (suspended, withdrawn and terminated)

Reasons to buy

- Understand the dynamics of a particular indication in a condensed manner
- Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more
- Obtain discontinued trial listing for trials across the globe
- Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies

Table Of Contents

Urinary Tract Infections Global Clinical Trials Review, H2, 2014
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 5
Introduction 6
Urinary Tract Infections 6
Report Guidance 6
Clinical Trials by Region 7
Clinical Trials and Average Enrollment by Country 8
Top Five Countries Contributing to Clinical Trials in Asia-Pacific 10
Top Five Countries Contributing to Clinical Trials in Europe 11
Top Countries Contributing to Clinical Trials in North America 12
Top Five Countries Contributing to Clinical Trials in Middle East and Africa 13
Top Five Countries Contributing to Clinical Trials in Central and South America 14
Clinical Trials by G7 Countries: Proportion of Urinary Tract Infections to Infectious Disease Clinical Trials 15
Clinical Trials by Phase in G7 Countries 16
Clinical Trials in G7 Countries by Trial Status 17
Clinical Trials by E7 Countries: Proportion of Urinary Tract Infections to Infectious Disease Clinical Trials 18
Clinical Trials by Phase in E7 Countries 19
Clinical Trials in E7 Countries by Trial Status 20
Clinical Trials by Phase 21
In Progress Trials by Phase 22
Clinical Trials by Trial Status 23
Clinical Trials by End Point Status 24
Unaccomplished Trials of Urinary Tract Infections 25
Subjects Recruited Over a Period of Time 29
Clinical Trials by Sponsor Type 30
Prominent Sponsors 31
Top Companies Participating in Urinary Tract Infections Therapeutics Clinical Trials 32
Prominent Drugs 33
Latest Clinical Trials News on Urinary Tract Infections 34
Oct 06, 2014: Tetraphase Pharmaceuticals Announces Initiation of Pivotal Portion of IGNITE 2 Phase 3 Trial of Eravacycline in cUTI 34
Clinical Trial Profiles 35
Clinical Trial Overview of Top Companies 35
Merck and Co., Inc. 35
Clinical Trial Overview of Merck and Co., Inc. 35
Zambon Company S.p.A. 36
Clinical Trial Overview of Zambon Company S.p.A. 36
Johnson and Johnson 37
Clinical Trial Overview of Johnson and Johnson 37
GlaxoSmithKline plc 38
Clinical Trial Overview of GlaxoSmithKline plc 38
AstraZeneca PLC 39
Clinical Trial Overview of AstraZeneca PLC 39
Astellas Pharma Inc. 40
Clinical Trial Overview of Astellas Pharma Inc. 40
Janssen Pharmaceuticals, Inc. 41
Clinical Trial Overview of Janssen Pharmaceuticals, Inc. 41
Daiichi Sankyo Company, Limited 42
Clinical Trial Overview of Daiichi Sankyo Company, Limited 42
Tetraphase Pharmaceuticals Inc. 43
Clinical Trial Overview of Tetraphase Pharmaceuticals Inc. 43
Actavis plc 44
Clinical Trial Overview of Actavis plc 44
Clinical Trial Overview of Top Institutes / Government 45
National Center for Complementary and Alternative Medicine 45
Clinical Trial Overview of National Center for Complementary and Alternative Medicine 45
U.S. Department of Veterans Affairs 46
Clinical Trial Overview of U.S. Department of Veterans Affairs 46
Assistance Publique - Hopitaux de Paris 47
Clinical Trial Overview of Assistance Publique - Hopitaux de Paris 47
Lawson Health Research Institute 48
Clinical Trial Overview of Lawson Health Research Institute 48
University of Washington 49
Clinical Trial Overview of University of Washington 49
Medical University of Vienna 50
Clinical Trial Overview of Medical University of Vienna 50
Samsung Medical Center 51
Clinical Trial Overview of Samsung Medical Center 51
University of Pittsburgh 52
Clinical Trial Overview of University of Pittsburgh 52
Leiden University Medical Center 53
Clinical Trial Overview of Leiden University Medical Center 53
University of Missouri 54
Clinical Trial Overview of University of Missouri 54
Five Key Clinical Profiles 55
Appendix 79
Abbreviations 79
Definitions 79
Research Methodology 80
Secondary Research 80
About GlobalData 81
Contact Us 81
Disclaimer 81
Source 81

List of Tables
Urinary Tract Infections Therapeutics, Global, Clinical Trials by Region, 2014* 7
Urinary Tract Infections Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2014* 8
Urinary Tract Infections Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2014* 9
Urinary Tract Infections Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2014* 10
Urinary Tract Infections Therapeutics Clinical Trials, Europe, Top Five Countries, 2014* 11
Urinary Tract Infections Therapeutics Clinical Trials, North America, Top Countries, 2014* 12
Urinary Tract Infections Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries, 2014* 13
Urinary Tract Infections Therapeutics Clinical Trials, Central and South America, Top Five Countries, 2014* 14
Proportion of Urinary Tract Infections to Infectious Disease Clinical Trials, G7 Countries (%), 2014* 15
Urinary Tract Infections Therapeutics, G7 Countries, Clinical Trials by Phase, 2014* 16
Urinary Tract Infections Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2014* 17
Proportion of Urinary Tract Infections to Infectious Disease Clinical Trials, E7 Countries (%), 2014* 18
Urinary Tract Infections Therapeutics, E7 Countries, Clinical Trials by Phase, 2014* 19
Urinary Tract Infections Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2014* 20
Urinary Tract Infections Therapeutics, Global, Clinical Trials by Phase, 2014* 21
Urinary Tract Infections Therapeutics, Global, Clinical Trials In Progress by Phase 2014* 22
Urinary Tract Infections Therapeutics, Global, Clinical Trials by Trial Status, 2014* 23
Urinary Tract Infections Therapeutics Clinical Trials, Global, by End Point Status, 2014* 24
Urinary Tract Infections Therapeutics, Global, Suspended Clinical Trials, 2014* 25
Urinary Tract Infections Therapeutics, Global, Withdrawn Clinical Trials, 2014* 26
Urinary Tract Infections Therapeutics, Global, Terminated Clinical Trials, 2014* 27
Urinary Tract Infections Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2009-2013 29
Urinary Tract Infections Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2014* 30
Urinary Tract Infections Therapeutics Clinical Trials, Global, Key Sponsors, 2014* 31
Urinary Tract Infections Therapeutics Clinical Trials, Global, Top Companies by Phase, 2014* 32
Urinary Tract Infections Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2014* 33
Urinary Tract Infections Therapeutics Clinical Trials Market, Global, Clinical Trials by Merck and Co., Inc., 2014* 35
Urinary Tract Infections Therapeutics Clinical Trials Market, Global, Clinical Trials by Zambon Company S.p.A., 2014* 36
Urinary Tract Infections Therapeutics Clinical Trials Market, Global, Clinical Trials by Johnson and Johnson, 2014* 37
Urinary Tract Infections Therapeutics Clinical Trials Market, Global, Clinical Trials by GlaxoSmithKline plc, 2014* 38
Urinary Tract Infections Therapeutics Clinical Trials Market, Global, Clinical Trials by AstraZeneca PLC, 2014* 39
Urinary Tract Infections Therapeutics Clinical Trials Market, Global, Clinical Trials by Astellas Pharma Inc., 2014* 40
Urinary Tract Infections Therapeutics Clinical Trials Market, Global, Clinical Trials by Janssen Pharmaceuticals, Inc., 2014* 41
Urinary Tract Infections Therapeutics Clinical Trials Market, Global, Clinical Trials by Daiichi Sankyo Company, Limited, 2014* 42
Urinary Tract Infections Therapeutics Clinical Trials Market, Global, Clinical Trials by Tetraphase Pharmaceuticals Inc., 2014* 43
Urinary Tract Infections Therapeutics Clinical Trials Market, Global, Clinical Trials by Actavis plc, 2014* 44
Urinary Tract Infections Therapeutics Clinical Trials Market, Global, Clinical Trials by National Center for Complementary and Alternative Medicine, 2014* 45
Urinary Tract Infections Therapeutics Clinical Trials Market, Global, Clinical Trials by U.S. Department of Veterans Affairs, 2014* 46
Urinary Tract Infections Therapeutics Clinical Trials Market, Global, Clinical Trials by Assistance Publique - Hopitaux de Paris, 2014* 47
Urinary Tract Infections Therapeutics Clinical Trials Market, Global, Clinical Trials by Lawson Health Research Institute, 2014* 48
Urinary Tract Infections Therapeutics Clinical Trials Market, Global, Clinical Trials by University of Washington, 2014* 49
Urinary Tract Infections Therapeutics Clinical Trials Market, Global, Clinical Trials by Medical University of Vienna, 2014* 50
Urinary Tract Infections Therapeutics Clinical Trials Market, Global, Clinical Trials by Samsung Medical Center, 2014* 51
Urinary Tract Infections Therapeutics Clinical Trials Market, Global, Clinical Trials by University of Pittsburgh, 2014* 52
Urinary Tract Infections Therapeutics Clinical Trials Market, Global, Clinical Trials by Leiden University Medical Center, 2014* 53
Urinary Tract Infections Therapeutics Clinical Trials Market, Global, Clinical Trials by University of Missouri, 2014* 54

List of Figures
Urinary Tract Infections Therapeutics, Global, Clinical Trials by Region (%), 2014* 7
Urinary Tract Infections Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2014* 8
Urinary Tract Infections Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2014* 9
Urinary Tract Infections Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2014* 10
Urinary Tract Infections Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2014* 11
Urinary Tract Infections Therapeutics Clinical Trials, North America, Top Countries (%), 2014* 12
Urinary Tract Infections Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries (%), 2014* 13
Urinary Tract Infections Therapeutics Clinical Trials, Central and South America, Top Five Countries (%), 2014* 14
Proportion of Urinary Tract Infections to Infectious Disease Clinical Trials, G7 Countries (%), 2014* 15
Urinary Tract Infections Therapeutics, G7 Countries, Clinical Trials by Phase, 2014* 16
Urinary Tract Infections Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2014* 17
Proportion of Urinary Tract Infections to Infectious Disease Clinical Trials, E7 Countries (%), 2014* 18
Urinary Tract Infections Therapeutics, E7 Countries, Clinical Trials by Phase, 2014* 19
Urinary Tract Infections Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2014* 20
Urinary Tract Infections Therapeutics, Global, Clinical Trials by Phase (%), 2014* 21
Urinary Tract Infections Therapeutics, Global, Clinical Trials In Progress by Phase, 2014* 22
Urinary Tract Infections Therapeutics, Global, Clinical Trials by Trial Status, 2014* 23
Urinary Tract Infections Therapeutics Clinical Trials, Global, by End Point Status, 2014* 24
Urinary Tract Infections Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2009-2013 29
Urinary Tract Infections Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2014* 30
Urinary Tract Infections Therapeutics Clinical Trials, Global, Key Sponsors, 2014* 31
Urinary Tract Infections Therapeutics Clinical Trials, Global, Top Companies by Phase, 2014* 32
Urinary Tract Infections Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2014* 33
GlobalData Methodology 80

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
PharmaPoint: Atrial Fibrillation - Global Drug Forecast and Market Analysis to 2025

PharmaPoint: Atrial Fibrillation - Global Drug Forecast and Market Analysis to 2025

  • $ 10995
  • Industry report
  • August 2016
  • by Global Data

PharmaPoint: Atrial Fibrillation - Global Drug Forecast and Market Analysis to 2025 Summary Atrial fibrillation (AF) is the most common cardiac arrhythmia and is a heart condition that causes an irregula ...

PharmaPoint: Venous Thromboembolism - Global Drug Forecast and Market Analysis to 2025

PharmaPoint: Venous Thromboembolism - Global Drug Forecast and Market Analysis to 2025

  • $ 10995
  • Industry report
  • August 2016
  • by Global Data

PharmaPoint: Venous Thromboembolism - Global Drug Forecast and Market Analysis to 2025 Summary Venous thromboembolism (VTE) is a disease that includes a myriad of life-threatening disorders ranging from ...

PharmaPoint: Acute Coronary Syndrome - Global Drug Forecast and Market Analysis to 2025

PharmaPoint: Acute Coronary Syndrome - Global Drug Forecast and Market Analysis to 2025

  • $ 10995
  • Industry report
  • August 2016
  • by Global Data

PharmaPoint: Acute Coronary Syndrome - Global Drug Forecast and Market Analysis to 2025 Summary Cardiovascular diseases (CVD), including ischemic heart disease and stroke, are the leading causes of mortality ...

Ulcerative Colitis: Kol Insight

September 2016 $ 8085

Hepatitis C: Kol Insight

September 2016 $ 8085

Download Unlimited Documents from Trusted Public Sources

Therapy Market in New Zealand - Forecast

  • December 2016
    71 pages
  • Therapy  

  • New Zealand  

View report >

Insulin Market in the US

  • December 2016
    8 pages
  • Insulin  

  • United States  

View report >

Therapy Market in the UK

  • December 2016
    194 pages
  • Therapy  

    Infectious Dise...  

    Eye Disease  

  • United Kingdom  

View report >

ref:plp2014

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.